连菊感冒胶囊治疗风热感冒的疗效与安全性:随机对照试验研究方案
本方案描述一项多中心、随机、双盲、安慰剂对照的II期临床试验,计划招募240例风热感冒患者,按1:1:1:1随机分为高、中、低剂量组和安慰剂匹配组,疗程3天、随访5天,主要结局为全部症状消失时间。
要点
- 多中心、随机、双盲、安慰剂对照II期试验,计划纳入240例风热感冒患者。
- 分高、中、低剂量组和安慰剂匹配组,按1:1:1:1随机分配,疗程3天、随访5天。
- 主要结局为全部症状消失时间,次要结局包括主要症状及各次要症状消失时间等。
核心结论
- 本试验按中国食品药品监督管理局(CFDA)发布的规范设计,结果将为连菊感冒胶囊治疗风热感冒的疗效与安全性提供高质量证据,并帮助优化下一阶段III期临床试验的剂量。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照II期临床试验,计划招募240例风热感冒患者。
- 患者按1:1:1:1随机分配到高剂量组、中剂量组、低剂量组和安慰剂匹配组;疗程3天,随访5天。
- 主要结局为全部症状消失时间;次要结局包括主要症状和各次要症状消失时间、发热缓解时间、发热消退时间及中医症状和体征评分变化。
关键数值与推荐
- 主要结局指标为全部症状消失时间;次要结局包括主要症状和各次要症状消失时间、发热缓解时间、发热消退时间及中医症状和体征评分变化。
- 疗程为连续3天,随访5天;计划招募240例患者,按1:1:1:1随机分组。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The common cold is a common and frequent respiratory disease mainly caused by viral infection of the upper respiratory tract. Chinese herbal medicine has been increasingly prescribed to treat the common cold; however, there is a lack of evidence to support the wide utility of this regimen. This protocol describes an ongoing phase II randomized controlled clinical trial, based on the theory of traditional Chinese medicine (TCM), with the objective of evaluating the efficacy and safety of Lian-Ju-Gan-Mao capsules (LJGMC), a Chinese patent medicine, compared with placebo in patients suffering from the common cold with wind-heat syndrome (CCWHS). METHODS/DESIGN: This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial. A total of 240 patients will be recruited and randomly assigned to a high-dose group, medium-dose group, low-dose group, and placebo-matched group in a 1:1:1:1 ratio. The treatment course is 3 consecutive days, with a 5-day follow-up. The primary outcome is time to all symptoms' clearance. Secondary outcomes include time to the disappearance of primary symptoms and each secondary symptom, time to fever relief, time to fever clearance, and change in TCM symptom and sign scores. DISCUSSION: This trial is a well-designed study according to principles and regulations issued by the China Food and Drug Administration (CFDA). The results will provide high-quality evidence on the efficacy and safety of LJGMC in treating CCWHS and help to optimize the dose for the next phase III clinical trial. Moreover, the protocol presents a detailed and practical methodology for future clinical trials of drugs developed based on TCM. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR-IPR-15006504 . Registered on 4 June 2015.
引用
- Wang S, Jiang H, Yu Q, et al. Efficacy and safety of Lian-Ju-Gan-Mao capsules for treating the common cold with wind-heat syndrome: study protocol for a randomized controlled trial. Trials. 2017. PMID: 28057058. doi:10.1186/s13063-016-1747-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。